Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy

Bibliographic Details
Main Authors:	M. Peluso, P. Bacchetti, K. Ritter, S. Beg, P. Hunt, T. Henrich, J. Siliciano, R. Siliciano, G. Laird, S. Deeks
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020301308

Similar Items

Intact proviral DNA levels decline in people with HIV on antiretroviral therapy
by: J. Cyktor, et al.
Published: (2019-12-01)

OP 4.7 – 00121 Circulating immune predictors of intact HIV reservoir decay during long-term ART
by: M. Peluso, et al.
Published: (2022-12-01)

Intact Proviral DNA Analysis of the Brain Viral Reservoir and Relationship to Neuroinflammation in People with HIV on Suppressive Antiretroviral Therapy
by: Dana Gabuzda, et al.
Published: (2023-04-01)

HIV replication and evolution in patients on highly active antiretroviral therapy
by: Siliciano Robert F
Published: (2006-12-01)

OP 3.6 – 00023 Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation
by: J. Kufera, et al.
Published: (2022-12-01)

HIV Prevention and Treatment Fields Join Forces
by: Steven G. Deeks, et al.
Published: (2014-11-01)

Intra- and inter-individual HIV diversity limits the application of the intact proviral detection assay (IPDA)
by: Natalie N. Kinloch, et al.
Published: (2019-12-01)

PP 1.7 – 00051 Continuous decline of intact proviral DNA after two decades of antiretroviral therapy
by: M. Nühn, et al.
Published: (2022-12-01)

Contribution of antigenic exposure to the persistence of HIV-infected CD4 T cells in vivo
by: F. Simonetti, et al.
Published: (2019-12-01)

Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV
by: A.L. Hill, et al.
Published: (2015-12-01)

HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)
by: Natalie N. Kinloch, et al.
Published: (2021-01-01)

A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir
by: Claire N. Levy, et al.
Published: (2021-04-01)

Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
by: Sulggi A Lee, et al.
Published: (2016-01-01)

HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy
by: F. Harrison Omondi, et al.
Published: (2021-12-01)

HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy.
by: Aniqa Shahid, et al.
Published: (2022-11-01)

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.
by: Alison L Hill, et al.
Published: (2016-04-01)

Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1
by: Michael J. Peluso, et al.
Published: (2020-01-01)

PP 7.8 – 00060 Slowing or Reversal of Decay of Intact Proviruses Over Two Decades of Suppressive ART
by: J. Cyktor, et al.
Published: (2022-12-01)

Author Correction: HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)
by: Natalie N. Kinloch, et al.
Published: (2021-05-01)

PP 8.4 – 00061 Bispecific antibodies promote natural killer cell-mediated elimination of the HIV reservoir
by: N. Board, et al.
Published: (2022-12-01)

CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART
by: Valerie F. Boltz, et al.
Published: (2021-04-01)

Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform
by: Carolin Tumpach, et al.
Published: (2023-06-01)

Comparative HIV-1 Proviral Dynamics in Two Individuals That Maintained Viral Replication Control with or without Antiretroviral Therapy following Superinfection
by: Suwellen Sardinha Dias de Azevedo, et al.
Published: (2022-12-01)

Development of a highly sensitive and specific intact proviral DNA assay for HIV-1 subtype B and C
by: N. V. E. J. Buchholtz, et al.
Published: (2024-01-01)

Chemistry and Bioinformatics Considerations in Using Next-Generation Sequencing Technologies to Inferring HIV Proviral DNA Genome-Intactness
by: Guinevere Q. Lee
Published: (2021-09-01)

Intragenic proviral elements support transcription of defective HIV-1 proviruses.
by: Jeffrey Kuniholm, et al.
Published: (2021-12-01)

Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.
by: Alison L Hill, et al.
Published: (2016-08-01)

Understanding persistence of the latent reservoir
by: R.F. Siliciano
Published: (2017-12-01)

OP 3.2 – 00056 Clonally expanded HIV-1 proviruses with 5′-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management
by: F. Wu, et al.
Published: (2022-12-01)

PP 3.9 – 00146 Impact of time on antiretroviral therapy on the proviral reservoir in people living with HIV
by: S. Rutsaert, et al.
Published: (2022-12-01)

Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir
by: Zheng Wang, et al.
Published: (2018-02-01)

Next generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 reservoir size
by: M. Stone, et al.
Published: (2017-12-01)

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
by: Natalie F. McMyn, et al.
Published: (2023-09-01)

Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods.
by: Jennifer A White, et al.
Published: (2022-09-01)

Protocol for high-throughput reservoir quantification across global HIV subtypes using a cross-subtype intact proviral DNA assay
by: Carolyn S. Fish, et al.
Published: (2022-12-01)

Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection
by: Ya-Chi Ho, et al.
Published: (2015-10-01)

Damaging the Integrated HIV Proviral DNA with TALENs.
by: Christy L Strong, et al.
Published: (2015-01-01)

PP 4.8 – 00108 Presentation of cognate antigens by dendritic cells causes stochastic HIV expression
by: M. Moskovljevic, et al.
Published: (2022-12-01)

Dynamic Shifts in the HIV Proviral Landscape During Long Term Combination Antiretroviral Therapy: Implications for Persistence and Control of HIV Infections
by: Elizabeth M. Anderson, et al.
Published: (2020-01-01)

OP 3.7 – 00099 Cohort-specific Adaptation of the Intact Proviral DNA Assay (IPDA) to HIV-1 subtypes A1, D, and recombinants
by: S.N. Gowanlock, et al.
Published: (2022-12-01)